Breast Cancer

Cancer experts at the Sylvester Comprehensive Cancer Center: Annual Oncology Update shared important progress across a wide range of cancers — prostate cancer, breast cancer, colon cancer, and more — that was presented at the American Society of Clinical Oncology 2022 Annual Meeting, the largest gathering of cancer clinicians and scientists in the United States.

Shared insight on next-generation sequencing platforms, plasma- and tumor-based, for patients with late-stage HR+ breast cancer.

Expert oncologists identify molecular targets in breast cancer and review available testing platforms in the current treatment paradigm.

Key opinion leaders in breast cancer management share their excitement for data that will be released at the annual ASCO meeting in 2022 or the near future.

Before closing out their discussion on CDK4/6 inhibition in HR+/HER2- metastatic breast cancer, experts highlight remaining unmet needs in this setting.

Ismail Jatoi, MD, discusses the importance of individualized care when deciding whether to omit sentinel lymph node biopsy in patients over the age of 70 with clinically node-negative, estrogen receptor–positive, HER2-negative breast cancer.

The FDA has accepted and granted priority review to a supplemental biologics license application for the use of trastuzumab deruxtecan in the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received 1 prior therapy in the metastatic setting.

Panelists briefly consider the ongoing role of everolimus in relapsed/refractory HR+/HER2- breast cancer given recent shifts in the treatment paradigm.

Expert oncologists review novel ADCs in TNBC and consider how their approval may impact sequencing of therapy in this setting.

Focusing on the management of brain metastases in HER2+ metastatic breast cancer, panelists share trial data on tucatinib and trastuzumab deruxtecan.

Homing in on trastuzumab deruxtecan, T-DXd, expert panelists review recent safety data in the setting of HER2+ metastatic breast cancer.

Comprehensive insight on novel treatment approaches in the setting of relapsed/refractory HR+/HER2- breast cancer, including oral SERDs, SERMs, and ER PROTAC degraders.

Comprehensive discussion on the safety and efficacy profile of the antibody-drug conjugate (ADC) sacituzumab govitecan and managing ADC-related adverse events in patients with mTNBC.

Joyce O'Shaughnessy, MD, outlines the current role and ongoing research of CDK4/6 inhibitors in the treatment of patients with hormone receptor–positive, HER2-negative early stage breast cancer.

Broad perspectives on various novel mechanisms of action that may address acquired resistance to therapies for HR+/HER2- metastatic breast cancer.

Considerations for how novel antibody drug conjugates (ADCs) and selective androgen receptor modulators (SARMs) may respectively address mechanisms of resistance within HR+/HER2- metastatic breast cancer.

The European Commission has approved fam-trastuzumab deruxtecan-nxki for use as a single agent in adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received at least 1 anti–HER2-based regimen.

The Philippine FDA has granted approval to alpelisib in combination with fulvestrant for the treatment of patients with PIK3CA-mutated, HR-positive, HER2-negative advanced or metastatic breast cancer.

The European Medicines Agency has validated the marketing authorization application for trastuzumab duocarmazine for the treatment of patients with HER2-positive unresectable, locally advanced or metastatic breast cancer.

After reviewing a patient scenario of relapsed/refractory metastatic TNBC, expert oncologists elucidate use of sacituzumab govitecan in this setting.

Shifting their focus to the HR+/HER2+ setting of breast cancer, expert panelists consider the potential of CDK4/6 inhibition in light of clinical trial data.

Shared insight on the treatment armamentarium for patients diagnosed with HER2+ metastatic breast cancer.

Expert oncologists share insight on the prognosis of triple-negative breast cancer (TNBC) and broadly review current treatment options for patients.

A brief review of frontline combination strategies in the context of multiple driver pathways in HR+/HER2- breast cancer.

Before closing out their discussion on early-stage HER2+ breast cancer, expert oncologists define the value of escalating or deescalating therapy.